Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 57.26

-0.2%

11:29 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (7221)	10/23/2002 5:26:37 PM
From: Biomaven	Read Replies (1) of 52153

Just to show that Reuters can produce misleadingly bullish stories as well as their previous bearish misleading stories, here's one from today: Intermune says Actimmune shows benefit in study - Oct 23, 2002 04:53 PM (Reuters) finance.lycos.com BRISBANE, Calif, Oct 23 (Reuters) - InterMune Inc <ITMN.O> on Wednesday said preclinical and preliminary clinical data suggest that its Actimmune interferon gamma injection may prevent or reverse the development of cirrhosis. Based on this data, it said it expects in mid-2004 a major advance in the management of patients with advanced liver disease. In Phase II, multi-center, placebo-controlled study, 500 patients with severe liver fibrosis or early cirrhosis associated with hepatitis C infections were randomized to receive either placebo, 100 mcg of Actimmune or 200 mcg of Actimmune three times per week via subcutaneous injection.© Reuters 2002. You wouldn't know it from the story, but what actually happened is that ITMN completed enrollment in their Phase II trial.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next